Grünenthal reports strong 2023 results with record revenue and ...
Mar 25, 2024 · Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
Grünenthal_AR_23_v2
Loading ePaperGrünenthal_AR_23_v2
Mar 25, 2024 · Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions In 2023, Grünenthal generated €1.8 billion in revenues, …
Grünenthal delivers exceptional financial results in 2024, powered …
Mar 27, 2025 · Follow us on: LinkedIn: Grunenthal Group Instagram: grunenthal Click here for our Grünenthal Report 2024/2025 Grünenthal delivers exceptional financial results in 2024, …
Grünenthal Report 2023/2024
Strategy for growth Grünenthal’s portfolio of established medicines has outper-formed its respective markets. Since 2017, we have invested more than €2 billion in successful …
Our NOP compound became our first proprietary Grünenthal com-pound to enter clinical development since 2017. It is the frontrun-ner of our peripheral Nociceptin/orphanin peptide …
Unternehmenspublikationen | Medien | Grünenthal GmbH
Unsere Liste der Unternehmenspublikationen enthält den Nachhaltigkeitsbericht, den Verhaltenskodex sowie weitere geschäftsbezogene Materialien.
Grünenthal reports record 2021 full-year results
Grünenthal reports 2021 full-year results of €1.5 billion in net revenues with double-digit growth and major investments in portfolio and pipeline.
Grünenthal verkündet ein starkes Ergebnis für 2023: Rekordumsatz …
Mar 25, 2024 · Grünenthal wurde der Kategorie "risikoarm" zugeordnet. 1 Basierend auf einer internen Analyse der Grünenthal GmbH unter Verwendung von Daten aus IQVIA Forecast …
- [PDF]
GRT_Report_2021_RZ
Our NOP compound became our first proprietary Grünenthal com-pound to enter clinical development since 2017. It is the frontrun-ner of our peripheral Nociceptin/orphanin peptide …
Gaining further financial flexibility and investing in future growth Investments included measures to strengthen our business with QutenzaTM in the US. We see significant opportuni-ties for …
Welcome | Grunenthal
Welcome | Grunenthal
Grünenthal reports record 2021 full-year results
Grünenthal reports 2021 full-year results of €1.5 billion in net revenues with double-digit growth and major investments in portfolio and pipeline.
Gaining further financial flexibility and investing in future growth Investments included measures to strengthen our business with QutenzaTM in the US. We see significant opportuni-ties for …